Tigecycline failed to reach 'non-inferiority' in the clinical evaluable population, which was the primary objective in that study; cure rates were 67.9% for tigecycline and 78.2% for imipenem ...

Vipen Sethi started his journey with the Landmark Group in 1990. Today as CEO – Corporate, he is involved in driving corporate governance and recommending strategies to support growth. And what a job ...

Vipen Sethi started his journey with the Landmark Group in 1990. Today as CEO — Corporate, he is involved in driving corporate governance and recommending strategies to support growth. And what a job ...